What These Medicines Actually Are Mostly Plausible Some Hypothesis

You're about to hear a handful of names — psilocybin, MDMA, ketamine, ibogaine — usually wrapped in either breathless hype or old "hard drug" fear. This lesson sets both aside and shows you what the science actually says these compounds are, and how researchers think they might work.

Meet the medicines

The first honest thing to know: these are not one thing. In plain terms —

• Psilocybin — the active compound in "magic mushrooms." A classic psychedelic being studied for depression and end-of-life distress.
• MDMA — often called an "empathogen." It can soften fear and lift feelings of trust and connection Plausible — part of why it's being paired with talk therapy for PTSD in trials.
• Ketamine / esketamine — a dissociative anesthetic used in hospitals for decades. In low doses it can, for some people, rapidly ease severe depression Plausible.
• LSD and DMT — other classic psychedelics; DMT is the active ingredient in ayahuasca.
• Ibogaine — a plant-derived compound studied for addiction and, more recently, traumatic brain injury in veterans. It's also the one with the most serious heart-safety cautions.

The receptor story: 5-HT2A

Most classic psychedelics — psilocybin, LSD, DMT — work largely by switching on one particular serotonin receptor called 5-HT2A. Picture a docking port on the surface of your brain cells: when these molecules plug in, they temporarily change how different brain regions talk to one another, loosening rigid, stuck patterns of thought and perception. That the drugs bind this receptor is well-established chemistry; that this binding is what heals a person is still Plausible, not proven.

Not everything works this way. MDMA mainly floods the brain with serotonin and "bonding" signals; ketamine blocks a different receptor (NMDA) in the glutamate system; and ibogaine touches many systems at once — part of why it's powerful, and part of why it carries more risk.

The neuroplasticity idea (and its big asterisk)

One popular explanation for why a single session might matter for weeks is neuroplasticity — the brain's ability to rewire itself. In animals, a single psychedelic dose can trigger rapid growth of new connections between neurons, including a rise in a growth factor called BDNF and more complex branching of brain cells^[1]. A 2023 study proposed a specific route: psychedelics may bind directly to BDNF's receptor, TrkB^[2]. It's an elegant idea — and worth grading honestly as Plausible, because nearly all of it comes from cells and mice.

What the human trials actually show

Set the mechanisms aside for a moment: what happens to real patients? A few results stand out — all promising, all still early.

• MDMA for PTSD. A phase 3 trial paired MDMA with several preparation and integration therapy sessions and saw a large drop in PTSD severity versus placebo^[4]. That trial reported no signal of abuse or suicidality — but MDMA still raises heart rate and blood pressure, and combining it with certain antidepressants (including SSRIs many veterans take) can trigger a dangerous serotonin reaction. Plausible
• Psilocybin for depression. A small randomized trial found large antidepressant effects four weeks after treatment^[5] — encouraging, but only about two dozen people. Plausible
• Ketamine for severe depression. Esketamine performed about as well as standard ketamine for treatment-resistant depression, and both were generally well tolerated^[6]. Plausible

Proven, promising, and hype

• Promising and real: meaningful early trial results in PTSD and depression, and a brain-plasticity mechanism that looks promising in animals but is still unproven in people.
• Not yet proven: long-term benefit, who is helped most, how durable it is, and whether the animal "rewiring" story holds in humans at all.
• Hype to distrust: anyone promising a cure, "zero risk," or guaranteed results — or claiming you must "cleanse toxins," "decalcify" anything, or aggressively detox to make the medicine work. Those are marketing lines, not science.

The legal reality

Honesty includes the law. Federally, in the United States:

• Psilocybin, MDMA, LSD, DMT, and ibogaine are Schedule I — officially classified as having no accepted medical use and high abuse potential. Possessing or using them outside an authorized study is illegal.
• Ketamine is Schedule III — a legal anesthetic a doctor can prescribe.
• Esketamine (Spravato) is FDA-approved for treatment-resistant depression, given in certified clinics under supervision.
• MDMA is not FDA-approved. Despite strong trials, it has not cleared the FDA — so "MDMA therapy" is not a legal, approved treatment you can simply sign up for today.

Carry this out of the lesson: these are powerful, still-experimental tools with real promise and real limits — hopeful enough on the honest facts that no one needs to exaggerate them.